Top 10 favorite abstracts from ASCO 2015, chosen by Cleveland Clinic’s Hematologists and Medical Oncologists
Two studies show that a new combination immunotherapy regimen can produce remission in some patients and improve survival in metastatic melanoma and kidney cancer.
Costly hospital readmissions were a target of the Affordable Care Act, but a cancer diagnosis poses challenges. A Cleveland Clinic study proposes three simple steps to reduce readmission while protecting patients.
Precision medicine matches a tumor’s unique genetic information with a targeted therapeutic and can be highly effective — provided the therapy is available. Often it isn’t.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Practice variations in cancer treatment are inefficient and costly, but research shows that an evidence-based care path for NSCLC helps standardize treatment while preserving survival benefits and markedly decreasing costs.
New analysis of the phase III CATCH trial of blood-thinning treatments identifies two clinical indicators for recurrent venous thromboembolism: tumor venous compression and hepatobiliary cancer.
A retrospective study investigating the impact of BRAF mutation on overall survival and treatment response in metastatic brain melanoma patients shows that stereotactic radiosurgery improves survival in BRAF-positive patients.